Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: J Allergy Clin Immunol. 2021 Aug 21;149(3):1044–1059.e5. doi: 10.1016/j.jaci.2021.07.041

Figure 3.

Figure 3.

IFN-β effectively inhibits IL-33- or allergen-induced innate type 2 response in the lung. (A) Lung single-cell suspensions were cultured with indicated concentrations of IL-33 with serial dilution of IFN-α or IFN-β for 96 h. The levels of IL-5 and IL-13 in the supernatants were determined by ELISA. Data are presented as the mean ± SEM (n = 3 in each group) and are representative of three experiments. *p<0.05, compared with cells cultured without IFNs. (B) Experimental model for Panels B, C, D and E. (C) BAL and lung levels of IL-5 and IL-13 were analyzed by ELISA. Data are presented as the mean ± SEM (n = 4 in each group). *p<0.05, **p<0.01 between the groups indicated by horizontal lines. (D) ILC2s in the lung were analyzed by gating on the Lin−CD25+CD44high population. Representative scattergrams are shown. (E) The number of ILC2 cells are presented. Data are presented as the mean ± SEM (n = 4 in each group). **p<0.01 between the groups indicated by horizontal lines.